Profile: Bruno Sepodes, Europe's Orphan Chief (AKA Batman), Who Loves Companies To Get Help
This article was originally published in Scrip
Executive Summary
Bruno Sepodes is the chair of the European Medicines Agency's Committee for Orphan Medicinal Products, the body that effectively decides whether your product wins and keeps its orphan status. In Scrip's latest industry profile, he talked about helping companies chase their dreams, where they go wrong and how for 10 years he led a double life as a Body Balance instructor.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.